Idiopathic pulmonary fibrosis in detail

Reading File

search_medical_text

idiopathic pulmonary fibrosis etiology pathophysiology clinical features diagnosis

search_medical_text

idiopathic pulmonary fibrosis treatment management antifibrotic prognosis

search_medical_image

idiopathic pulmonary fibrosis HRCT usual interstitial pneumonia UIP pattern

GradeResponse

Here is a comprehensive overview of idiopathic pulmonary fibrosis (IPF):

Idiopathic Pulmonary Fibrosis (IPF)

Definition

IPF is a chronic, progressive, fibrosing interstitial pneumonia of unknown cause, associated with the radiological and histopathological pattern of Usual Interstitial Pneumonia (UIP). It occurs primarily in older adults and carries a poor prognosis. (ATS/ERS Guidelines, p. 2)

Epidemiology

Parameter	Detail
Age of onset	Typically >60 years (rare <50)
Sex	Male predominance (~2:1)
Prevalence	~13–20 per 100,000 (higher in older populations)
Incidence	Increasing globally

Risk factors:

Cigarette smoking (strongest environmental risk; ~75% of patients are current or ex-smokers)
Occupational dust exposures (wood, metal, agricultural dust)
Gastroesophageal reflux disease (GERD)
Viral infections (EBV, CMV, HHV-8)
Genetic predisposition — MUC5B promoter variant (rs35705950) is the most common genetic risk factor; also TERT, TERC, SFTPC, SFTPA2 mutations (telomere/surfactant biology)
Family history (familial IPF = ~5% of cases)

Pathophysiology

The prevailing model is one of aberrant wound healing rather than primary inflammation:

Repetitive alveolar epithelial injury → apoptosis of type II pneumocytes in genetically susceptible individuals
Dysregulated repair → abnormal activation and proliferation of fibroblasts/myofibroblasts
Fibroblastic foci form — hallmark histological feature — with excessive deposition of extracellular matrix (collagen)
Key mediators:
- TGF-β1 (master profibrotic cytokine)
- PDGF, VEGF, FGF
- Epithelial-mesenchymal transition (EMT)
- Oxidative stress, telomere shortening, senescence
Progressive architectural distortion → honeycombing → respiratory failure

The inflammatory cascade is now considered secondary, not causal — explaining why anti-inflammatory therapies fail.

Clinical Features

Symptoms

Progressive exertional dyspnea (insidious onset, months–years)
Dry, persistent cough (often refractory)
Fatigue, weight loss (late)
Rare: pleuritic chest pain

Signs

Bibasal fine inspiratory ("Velcro") crackles — hallmark
Clubbing (~50%)
Cyanosis and signs of pulmonary hypertension (right heart failure) in advanced disease

Diagnosis

Diagnosis requires multidisciplinary discussion (MDD) involving pulmonologist, radiologist, and pathologist. Key steps:

Step 1: Exclude Other Causes of ILD

Connective tissue disease (CTD-ILD): SLE, RA, SSc, PM/DM
Hypersensitivity pneumonitis (HP)
Drug-induced ILD (amiodarone, methotrexate)
Occupational/environmental ILD
Sarcoidosis

Step 2: High-Resolution CT (HRCT) — Pattern Classification

HRCT is the cornerstone of diagnosis. The UIP pattern is classified as:

HRCT Category	Features	Surgical Biopsy Needed?
Typical UIP	Bilateral, subpleural, basal-predominant; honeycombing ± traction bronchiectasis; no features against UIP	No
Probable UIP	Reticular pattern, traction bronchiectasis, no honeycombing; subpleural, basal	May need biopsy
Indeterminate for UIP	Subtle reticulation; may have features atypical for UIP	Often needs biopsy
Alternative diagnosis	Features suggesting another ILD	Biopsy or alternative workup

HRCT — Typical UIP Pattern

HRCT showing definite UIP pattern in IPF — bilateral subpleural honeycombing, traction bronchiectasis, and reticular opacities with basal predominance

Axial HRCT demonstrating the "definite UIP" pattern: bilateral subpleural honeycombing (clustered thick-walled cysts), traction bronchiectasis within fibrotic areas, and a peripheral reticular pattern with basal predominance — classic for IPF.

Step 3: Histopathology (when needed)

Surgical lung biopsy (VATS) or transbronchial lung cryobiopsy (TBLC) — TBLC now conditionally recommended as a less invasive alternative.

UIP histologic features:

Fibroblastic foci (key feature)
Patchy fibrosis with temporal heterogeneity (old + new fibrosis coexisting)
Honeycombing (subpleural, basal)
Minimal inflammation

Step 4: Additional Diagnostics

Test	Purpose
PFTs	Restrictive pattern: ↓TLC, ↓FVC, ↓DLCO, normal or ↑FEV1/FVC
6-Minute Walk Test (6MWT)	Exercise capacity, baseline and monitoring
BAL (bronchoalveolar lavage)	Exclude HP, eosinophilia, infection
Serologies (ANA, RF, anti-CCP, anti-Jo-1, etc.)	Exclude CTD-ILD
Genomic classifier testing	Peripheral blood test (Envisia) to distinguish UIP vs non-UIP — newly addressed in 2022 guidelines
Echocardiography	Screen for pulmonary hypertension
Sleep study	Screen for OSA (common comorbidity)

Differential Diagnosis

Condition	Key Distinguishing Feature
HP (chronic)	Upper/mid-lobe predominance, centrilobular nodules, exposure history
NSIP	Bilateral GGO, subpleural sparing, younger age, CTD association
Cryptogenic organizing pneumonia	Consolidation, peribronchovascular, responds to steroids
Sarcoidosis	Upper lobe, lymphadenopathy, non-caseating granulomas
Asbestosis	Pleural plaques, occupational history
CTD-ILD (RA, SSc)	Serological markers, systemic features

Management

(ATS/ERS Guidelines, p. 18)

Pharmacological Treatment

Antifibrotic Agents (Disease-Modifying)

Drug	Mechanism	Dose	Key Side Effects
Pirfenidone (Esbriet)	Anti-inflammatory, antifibrotic, antioxidant; inhibits TGF-β	2403 mg/day (tid)	Nausea, rash, photosensitivity, ↑LFTs
Nintedanib (Ofev)	Tyrosine kinase inhibitor (PDGFR, FGFR, VEGFR)	150 mg bid	Diarrhea, nausea, ↑LFTs, teratogenic

Both drugs reduce FVC decline by ~50% and reduce acute exacerbation risk. They do not reverse fibrosis but slow progression. Both are conditionally recommended by ATS/ERS guidelines; choice is individualized based on comorbidities and tolerability.

Not recommended: Corticosteroids (alone or combined with azathioprine + N-acetylcysteine), anticoagulation (warfarin), sildenafil for ILD-related dyspnea, and imatinib.

Non-Pharmacological Management

Intervention	Indication/Detail
Long-term oxygen therapy	Resting hypoxemia (SpO₂ <88%) or exertional desaturation
Pulmonary rehabilitation	Improves exercise tolerance, dyspnea, QoL
Lung transplantation	Definitive treatment; single or bilateral; refer early (at diagnosis if high-risk features); 5-year survival ~50%
Antacid therapy (PPIs/H2 blockers)	GERD treatment recommended (GERD highly prevalent; micro-aspiration may drive injury)
Palliative care	Symptom management (cough, dyspnea, anxiety, depression); discuss early

Comorbidity Management

Comorbidity	Approach
Pulmonary hypertension	Evaluate with echo/RHC; consider targeted therapy
OSA	CPAP; very common in IPF
Lung cancer	IPF is an independent risk factor; screen per guidelines
GERD	Treat aggressively
Coronary artery disease	Common in same demographic

Acute Exacerbations of IPF (AE-IPF)

Definition: Acute worsening with new bilateral GGO/consolidation on HRCT (beyond background UIP) with no identifiable cause
Triggers: Infection, aspiration, surgery, bronchoscopy — or idiopathic
Incidence: ~5–10%/year
Management:
- High-dose corticosteroids (empiric, evidence limited)
- Broad-spectrum antibiotics (to cover secondary infection)
- Supportive oxygen; mechanical ventilation generally NOT recommended (poor outcomes)
- ICU admission often futile — goals-of-care discussion essential
Prognosis: In-hospital mortality ~50%; median survival after AE-IPF ~3–4 months

Monitoring

Patients should be evaluated every 3–6 months (more frequently if progressing) with:

Spirometry + DLCO
6MWT
HRCT (annually or if significant change)
Assessment for transplant candidacy

Markers of disease progression / poor prognosis:

FVC decline ≥10% over 6–12 months
DLCO decline ≥15%
Desaturation during 6MWT
Hospitalization for respiratory cause
Development of pulmonary hypertension

Prognosis

Parameter	Data
Median survival from diagnosis	3–5 years
5-year mortality	~80%
Cause of death	Respiratory failure (most common), AE-IPF, lung cancer, cardiovascular

IPF follows a variable course — most patients show slow, steady decline; some have accelerated decline with AEs; a minority are stable for years.

Key Guidelines

ATS/ERS/JRS/ALAT 2022 Clinical Practice Guidelines — the most current evidence-based guideline (ATS/ERS, p. 2, 18)
Available at: American Journal of Respiratory and Critical Care Medicine

Summary Algorithm

Suspected IPF (older adult, bilateral basal crackles, dyspnea)
        ↓
Exclude alternative ILD causes (CTD serology, drug Hx, exposure Hx)
        ↓
HRCT
   ├── Typical UIP → Diagnose IPF (no biopsy needed)
   ├── Probable UIP → Consider biopsy / genomic classifier / MDD
   └── Indeterminate → Biopsy (TBLC or surgical) → MDD
        ↓
Confirm IPF
        ↓
Start antifibrotic (nintedanib or pirfenidone)
+ O₂, pulmonary rehab, GERD treatment
+ Early lung transplant referral if high-risk
+ Monitor every 3–6 months
+ Palliative care integration

This is a shared conversation. Sign in to Orris to start your own chat.